HK1092016B - Antiviral agent and fibers and antiviral members using the same - Google Patents

Description

Antiviral agent, fiber using the same, and antiviral member

Technical Field

The present invention particularly relates to an antiviral agent particularly effective against coronavirus and the like, a fiber using the same, and an antiviral member.

Background

Heretofore, in order to facilitate industrial production, maintain high trapping performance, inactivate viruses and prevent them from being re-diffused, for example, in japanese patent application laid-open No. 8-333271, a mask using a nonwoven fabric containing an extract component of tea has been proposed.

Further, as a filter material for a mask for trapping bacteria, viruses, animal and plant cells, harmful gases, malodorous components, dust, smoke, pollen and the like in the air and allowing other components to permeate therethrough and a mask using the same, for example, a sheet-like organic polymer substrate is proposed in, for example, japanese patent application laid-open No. 5-115572, which mask holds particles of a calcium phosphate compound having a Ca/P ratio of 1.0 to 2.0 in gauze and comprises a filter material for a mask having a plurality of fine vent holes laminated in 1 or more layers, and has exhalation resistance5.0mmH₂O or below.

However, although any of the above masks demonstrated experimental efficacy against bacteria in the air, their antiviral efficacy has not been experimentally demonstrated.

Furthermore, antiviral agents, such as enzyme inhibitors, which are effective against severe acute respiratory infectious disease (SARS) virus and influenza virus have been recently developed, but these agents exert their effects after the virus infects cells, and do not cause the infectivity of the virus to disappear by direct action with viral particles.

The present invention has been made to solve the above problems, and an object of the present invention is to provide an antiviral agent which is capable of preventing entry of a virus into cells by eliminating the infectivity of the virus and is suitable for use in an antiviral member such as a mask or a filter, and a fiber and an antiviral member using such an antiviral agent, and which has an experimentally proven effect.

Disclosure of Invention

The antiviral agent described in scheme 1 contains an oxide and/or a hydroxide.

Here, "oxide and/or hydroxide" is meant to include the case of oxide, hydroxide, and both oxide and hydroxide.

The oxide is changed into a hydroxide by contact with water (hydration or digestion), and the hydroxide is changed into an oxide by removing water therefrom.

Such an oxide and/or hydroxide can be obtained by firing (calcining) a mineral or the like to partially hydrate (digest), can be obtained by firing (calcining) a seashell or the like to partially hydrate (digest), can be obtained by production of a chemical or the like, and can be obtained by another method.

The antiviral agent described in the embodiment 2 is an antiviral agent described in the embodiment 1, wherein the oxide and/or hydroxide thereof contains calcium and/or magnesium.

The antiviral agent described in the embodiment 3 is prepared from a carbonate mineral as a powder of an oxide and/or hydroxide of the antiviral agent described in the embodiment 1.

As the "carbonate mineral" used herein, there may be mentioned, for example, calcite (calcite), nepheline (aragonite), and other calcium (more particularly, CaCO)₃) Carbonate mineral as main ingredient, dolomite (dolomite), other calcium and magnesium (more particularly CaMg (CO)₃)₂) Carbonate mineral as main component.

The antiviral agent described in the embodiment 4 is the antiviral agent described in the embodiment 3, wherein the carbonate mineral contains calcium and/or magnesium.

The antiviral agent described in scheme 5 is a powder comprising dolomite (dolomite) calcined and partially hydrated.

The fiber according to claim 6, wherein the antiviral agent according to any one of claims 1 to 5 is retained in the fiber.

Here, the term "fiber" used in the present specification includes both woven fabrics and nonwoven fabrics.

The antiviral agent according to any one of claims 1 to 5 may be retained in the fiber by adhering the antiviral agent to the surface of the fiber with a binder and mixing the antiviral agent with a resin.

More specifically, for example, there is a method of mixing the antiviral agent described in any one of embodiments 1 to 5, a binder (e.g., urethane), water and, if necessary, a dispersant, dispersing the antiviral agent in an aqueous solution, preparing an aqueous solution in which the antiviral agent is partially dissolved, immersing the fiber in the aqueous solution, and drying the fiber.

Examples of the fibers include hollow fibers in which the antiviral agent described in any one of claims 1 to 5 is dispersed in a resin (e.g., polyethylene), and composite fibers in which a resin (e.g., polypropylene) is used as a core material.

The antiviral agent component described in scheme 7 uses the fiber described in scheme 6.

Examples of the antiviral member include a filter for air cleaning used for a face mask, an air conditioner, and the like, and clothes such as gloves, sheets, curtains, aprons, white gowns, protective clothing, and the like.

An antiviral agent according to claim 8 is a reagent containing the antiviral agent according to any one of claims 1 to 5 in a liquid.

The term "liquid" used herein includes alcohols such as methanol, ethanol and isopropanol, water, a mixed liquid of the alcohols and water, and a liquid containing chlorhexidine, benzalkonium chloride, benzethonium chloride, alkylpolyaminoethyl glycine, other amphoteric surfactants.

The antiviral member according to claim 9 is a container for containing the antiviral agent according to claim 8.

The antiviral member according to claim 10 is the antiviral member according to claim 9, and the container is a spray bottle.

The antiviral agent according to any one of aspects 1 to 5 can prevent viruses from entering cells, and therefore can be suitably used for air cleaning filters used in face masks, air conditioners, and the like, and clothes such as gloves, sheets, curtains, aprons, gowns, protective clothing, and the like.

The fiber described in the embodiment 6 retains the antiviral agent described in any one of the embodiments 1 to 5 in the fiber, and when the virus passes through the fiber, the virus is inactivated by contact with the antiviral agent.

Accordingly, when the fiber is used as an antiviral member, infection of a human body with coronavirus, influenza virus, or the like can be prevented.

The antiviral member described in scheme 7 can prevent infection with severe acute respiratory infectious disease (SARS) virus and influenza virus by using the fiber described in scheme 6.

For example, when an air cleaning filter such as a face mask or an air conditioner, or clothes such as gloves, sheets, curtains, aprons, gowns, and protective clothing are manufactured using the fiber described in embodiment 6, coronavirus, influenza virus, and the like, which come into contact with their antiviral members, are inactivated, and thus the infectivity is lost.

Accordingly, when the fibers described in scheme 6 are used and attached to clothes such as gloves, bed sheets, aprons, gowns, protective clothing, etc., infection with Severe Acute Respiratory Syndrome (SARS) virus, influenza virus, etc. can be prevented.

For example, when an air cleaning filter such as a mask or an air conditioner is manufactured using the fiber described in embodiment 6, the filter can be inactivated when coronavirus, influenza virus, or the like passes through the filter.

Accordingly, when the air cleaning filter using the fiber described in claim 6 is incorporated into an air conditioner or the like, it is possible to prevent infection with Severe Acute Respiratory Syndrome (SARS) virus, influenza, or the like.

Further, the antiviral agent described in scheme 8 may be contained in a container in which clothes and other parts are impregnated to provide an antiviral effect on the clothes and other parts, the clothes and other parts contaminated with viruses can be subjected to a virus elimination operation by themselves, or the antiviral agent may be added to a spray bottle and sprayed at a place where it is considered to be contaminated with viruses.

Further, the antiviral agent of the antiviral member is not volatile, and can maintain the antiviral effect for a long period of time in clothes and other members and places where it is considered to be contaminated with viruses.

In the antiviral member according to the embodiment 9, the antiviral agent according to the embodiment 8 is contained in a spray bottle, and the antiviral agent is sprayed to a place where the virus is considered to be contaminated, whereby a virus removing operation can be performed to the place where the virus is considered to be contaminated.

Furthermore, the antiviral agent of the antiviral member is not volatile, and thus can maintain the antiviral effect for a long period of time in a place where it is considered to be contaminated with viruses.

Further, a thin, white powder appears where the antiviral agent of the antiviral member is sprayed, and it is possible to easily distinguish between a place where the antiviral agent of the present invention has been sprayed and a place where the antiviral agent of the present invention has not been sprayed, thereby bringing about an effect that an operator easily performs the antiviral agent spraying operation at a place considered to be contaminated with viruses.

Further, the place where the antiviral agent of the antiviral member is sprayed can be easily returned to the original state by wiping with a rag.

Drawings

FIG. 1 is a graph showing the results of an experiment for confirming the effect of the antiviral agent of the present invention.

FIG. 2 is a diagram illustrating samples used in experiments for confirming the effects of the antiviral agent of the present invention.

FIG. 3 is a graph showing the results of an experiment for confirming the effect of the antiviral agent of the present invention.

FIG. 4 is a graph showing the results of an experiment for confirming the effect of the antiviral agent of the present invention.

FIG. 5 is a graph showing the chemical composition (X-ray diffraction result) of dolomite used.

FIG. 6 is a graph showing the chemical composition (X-ray diffraction result) of dolomite after preliminary calcination (calcination).

FIG. 7 is a graph showing the chemical composition (X-ray diffraction result) of a powder (antiviral agent of the present invention) obtained by calcining (calcining) dolomite and partially hydrating (digesting) the dolomite.

In FIG. 8, (a) and (b) are perspective views showing the appearance of a face mask using the antiviral agent of the present invention.

Fig. 9 is a sectional view schematically showing the structure of the filter member 2 of the mask 1 shown in fig. 8(a), and in fig. 9, (a) is a view schematically showing a state in which dust, pollen, bacteria, virus, and the like in the air are blocked by the mask when a person inhales from the outside, and (b) is a view schematically showing a state in which bacteria, virus, saliva, and the like are blocked by the mask when a person exhales to the outside.

Detailed Description

To describe the present invention in more detail, an antiviral agent, a mask and a filter using the same will be described with reference to the accompanying drawings.

(example 1)

Processes for the preparation of antiviral agents are described herein.

In this example, a case where dolomite is used as a raw material will be described.

The dolomite is first calcined in the atmosphere.

In this case, the calcination (calcination) is carried out at a temperature in the range of 700 to 1300 ℃, preferably 700 to 1100 ℃ for 14 to 15 hours.

This is because when dolomite is calcined at temperatures exceeding 1300 ℃, the calcined product will vitrify. To prevent this, the dolomite is calcined at a temperature in the range of 700 ℃ to 1300 ℃, preferably 700 ℃ to 1100 ℃.

That is, the calcined product is more preferably a light calcined product (this example is light calcined dolomite) than a heavy calcined product (this example is calcined dolomite).

According to the above steps, a material having calcium oxide (CaO) and magnesium oxide (MgO) as main components can be obtained.

The calcined dolomite is then partially hydrated (digested) by placing it in water which is also at an elevated temperature. The water content of the partially hydrated product is preferably in the range of 3 w/w% or more and 7 w/w% or less.

Next, the calcined and partially hydrated dolomite product is pulverized or sieved with a pulverizer (dry pulverizer and/or wet pulverizer) such as a ball mill until the average particle diameter of the particles is in the range of 0.1 to 60 μm. This is because the antiviral action of the partially hydrated product obtained by calcining dolomite having a particle size of more than 60 μm tends to be weakened. And observing the calcined dolomite and partially hydrated product with an electron microscope, wherein 2-order particles and 1-order particles of 1-order particles are aggregated, the average particle size of the particles is the average particle size of the 2-order particles, and the average particle size of the 1-order particles is in the range of 1nm to 200 nm.

In the raw material dolomite, calcium carbonate accounts for 31-35 wt% of the dolomite per unit weight in terms of calcium oxide, magnesium carbonate accounts for 17-20 wt% of the dolomite per unit weight in terms of magnesium oxide, and the ignition loss component accounts for 44-47 wt% of the dolomite per unit weight. Furthermore, the endothermic peak obtained from the raw dolomite according to the differential thermal analysis is within the range of the typical endothermic peak temperature of domestic dolomite in either of the first stage and the second stage.

Moreover, the raw material dolomite comprises the following components in percentage by weight: a loss on ignition (Ig. loss) of 24.0 to 28.0 parts by weight in a state of being calcined (calcined) and partially hydrated (digested), and an insoluble residue (SiO)₂+ instol.) 0.001 to 1.0 parts by weight of iron oxide and aluminum oxide (Fe)₂O₃+Al₂O₃) 0.001 to 1.0 part by weight, 40 to 55 parts by weight of calcium oxide (CaO), and 23 to 30 parts by weight of magnesium oxide (MgO).

(example 2)

The antiviral test method of the powder obtained according to example 1, obtained by roasting (calcining) dolomite and partially hydrating (digesting) and the results thereof are shown here.

First, 12% by weight of the powder obtained in example 1 by calcining (calcined) dolomite and partially hydrating (digesting) and 5% by weight of urethane were dispersed and dissolved in pure water to prepare an aqueous solution (hereinafter referred to as "experimental solution").

Urethane is added as a binder to be attached to the fibers, and a dispersant may be appropriately added to the experimental solution in order to prevent precipitation of powder obtained by firing (calcining) dolomite and partial hydration (digestion).

As the viruses to be tested, avian infectious bronchitis virus ボ - デット 42 strain (Coronaviridae), newcastle disease virus ラソ - タ strain (Paramyxoviridae), influenza virus A/Aizhi/2/68 (H3N2) (a strain isolated from human body), and influenza virus A/コハクチョウ/islet root/499/83 (H5N3) (a strain isolated from bird body) were used.

(Experimental method 1)

0.9ml of each of the virus solutions and 0.1ml of the test solution were added to the sterilized test tube, mixed well, and allowed to stand at 4 ℃ for 10 minutes.

Then, 0.09ml of the mixture of the virus solution and the test solution was added dropwise to a test tube containing 0.81ml of a diluent of PBS (phosphate buffered saline (PBS) having a pH of 7.2), diluted 10-fold, and mixed thoroughly. This operation was repeated 9 times to prepare 10^-1、10^-2、10^-3、10^-4、10^-5、10^-6、10^-7、10^-8、10^-9The diluent (2).

The virus solutions mixed in each dilution were inoculated into the urethra of 3 SPF-developed eggs of 10 days of age, each inoculated with 0.2 ml.

The inoculated developing eggs were incubated at 37 ℃ for an additional 3 days (6 days for avian infectious bronchitis virus).

Eggs were examined daily and the development of chicken embryos stopped within 24 hours after virus inoculation was excluded from the experiment as an accident.

In addition, a comparative example using a Phosphate Buffered Saline (PBS) solution having a pH of 7.2 was set to perform the same operation instead of the mixed solution of the virus solution and the test solution.

And (4) placing the inoculated and developed eggs after the incubation is finished according to the regulation into a refrigerator and standing for one night.

The next day, urine was collected from the eggs inoculated with the avian infectious bronchitis virus, and the urine was mixed with a suspension of 0.5% chicken red blood cells in a test tube to examine the presence or absence of coagulation of the red blood cells. This is because influenza virus and newcastle disease virus have chicken red blood cell cohesive energy.

Thus, the antiviral effect can be determined by examining the presence or absence of agglutination of the chicken erythrocytes inoculated with each developing egg, which is calculated according to the method of Reed and Muench (ref: Reed, L, J.,. Muench, H.: A single method of immunological non-center endings. am. J. Hyg.27, 493 497 (1938)).

In the case of avian infectious bronchitis virus, the virus titer was determined by visually observing the presence or absence of a fetal shape, i.e., fetal dysplasia (dwarfism) and contracture (phenomenon of fetal looping), which are characteristic of the virus when infected.

The results are shown in FIG. 1.

As can be seen from the results of fig. 1, the infectivity of the virus can be reduced to less than 10 ten thousandths by mixing the 1.2 wt% solution prepared from the powder obtained by calcining (dolimite) and partially hydrating (digesting) dolomite with the virus which is used in the experiment and has infectivity to both animals and humans and causes respiratory diseases for only 10 minutes.

Comparative example

Instead of the mixture of the virus solution and the test solution, a solution in which 5 wt% urethane was dispersed and dissolved in pure water was prepared, 0.09ml of this solution was collected, and 0.81ml of PBS (phosphate buffered saline (PBS) having a pH of 7.2) was added dropwise to the solutionIn a tube releasing the solution, dilute 10 times and mix well. This operation was repeated 9 times to prepare 10^-1、10^-2、10^-3、10^-4、10^-5、10^-6、10^-7、10^-8、10^-9The diluent (2).

The same experiment as in experimental method 1 was performed below, but no antiviral effect was found.

(example 3)

The same experiment as experimental method 1 was performed except that slaked lime was used instead of the powder obtained by calcining (calcining) dolomite (dolomite) and partially hydrating (digesting) it.

As a result, although slaked lime is considered to have an antiviral effect, it is considered that the antiviral effect is strong in the case of using a powder obtained by calcining (calcining) dolomite (dolimite) and partially hydrating (digesting) the same.

(example 4)

The same experiment as experimental method 1 was performed except that the powder obtained by calcining (calcining) the shell and partially hydrating (digesting) it was used instead of the powder obtained by calcining (calcining) the dolomite (dolomite) and partially hydrating (digesting) it.

As a result, it is considered that a powder obtained by baking (calcining) shells and partially hydrating (digesting) the shells also has an antiviral effect.

(example 5)

Here, an example of a method for producing a fiber in which a powder is held in a woven fabric or a nonwoven fabric, and a method for producing an antiviral member (in this example, a mask) using the fiber produced by the production method, and a powder in which dolomite (dolomite) is calcined and partially hydrated (digested) are used as the remaining fiber, will be described.

First, a powder obtained by calcining (calcining) dolomite (dolomite) and partially hydrating (digesting) the calcined dolomite, urethane, and a dispersant as necessary are dispersed and dissolved in water to prepare an aqueous solution.

Next, the fibers (woven fabric or nonwoven fabric) are impregnated with the aqueous solution, and then dried.

Through the above steps, a fiber (woven fabric or nonwoven fabric) holding a powder obtained by calcining (calcining) dolomite (dolomite) and partially hydrating (digesting) it is manufactured.

Next, using fibers (woven fabric or nonwoven fabric) holding a powder obtained by calcining (calcining) dolomite (dolimite) and partially hydrating (digesting) it, a face mask was produced.

The mask uses fibers (woven or nonwoven fabric) holding powder obtained by calcining (calcining) dolomite (dolomite) and partially hydrating (digesting) it, so that when the mask is worn, infection by severe acute respiratory infectious disease (SARS) virus and influenza virus can be prevented.

(example 6)

Another example of a method for producing a fiber in which a powder obtained by calcining (calcining) dolomite (dolomite) and partially hydrating (digesting) the same is retained on a woven or nonwoven fabric, and a filter produced by the production method using a fiber retaining a powder obtained by calcining (calcining) dolomite (dolomite) and partially hydrating (digesting) the same are described.

First, a powder obtained by calcining (calcining) dolomite (dolomite) and partially hydrating (digesting) it is mixed in polyethylene particles.

Then, a resin molding machine for manufacturing the composite fiber is prepared.

The resin molding machine is such that an inner nozzle and an outer nozzle are provided at the tip end, the outer nozzle is generally concentrically provided outside the inner nozzle, the resin supplied to the 1 st raw material hopper is ejected (extruded) from the outer nozzle, and the resin supplied to the 2 nd raw material hopper is ejected (extruded) from the inner nozzle. Next, a mixture obtained by calcining dolomite (dolomite) and partially hydrating (digesting) it was supplied into the 1 st raw material hopper of the resin molding machine, and the mixture was mixed with polyethylene pellets to obtain a powder.

Polypropylene particles used as a core material are supplied into a 2 nd raw material hopper of the resin molding machine.

Next, a molten resin of polypropylene and a polyethylene in which powder is dispersed are injected (extruded) from an inner nozzle and an outer nozzle provided at the tip of the resin molding machine, respectively, and drawn to produce a hollow fiber in which powder is dispersed in polyethylene and a composite fiber using polypropylene as a core material thereof. The powder is obtained by roasting (calcining) dolomite (dolomite) and partially hydrating it.

Next, a filter was produced using the fiber.

Since the filter uses a fiber holding a powder obtained by calcining dolomite (dolimite) and partially hydrating (digesting) the dolomite, the coronavirus and the influenza virus are inactivated when they pass through the filter in a transmission device of an air conditioner by using the filter in an air cleaning part of the air conditioner or the like.

Accordingly, when the filter is used in an air cleaning component such as an air conditioner, infection with Severe Acute Respiratory Syndrome (SARS) virus and influenza virus can be prevented.

In this example, although the example of using the composite fiber in which polypropylene is used as the core material and the hollow fiber is a powder obtained by mixing and burning (calcined) dolomite (dolimite) with polyethylene particles and partially hydrating (digesting) the dolomite (dolimite), the fiber mixed with the powder may be used alone, and the resin used may be a resin other than polypropylene or polyethylene.

(example 7)

An example of the use of the antiviral agent of the present invention is illustrated herein.

A product obtained by calcining dolomite and partially hydrating the calcined dolomite is pulverized using a pulverizer (wet pulverizer) such as a ball mill so that the average particle diameter of the secondary particles of the particles is in the range of 0.1 to 1 μm, thereby obtaining a slurry.

Next, the antiviral agent of the present invention is contained in a spray bottle, and a liquid is added.

The content of the antiviral agent of the present invention is preferably 0.1% or more, more preferably 0.2% or more, relative to the liquid.

The content of the antiviral agent of the present invention is 0.1% to 2% relative to the liquid.

More preferably, the antiviral agent of the present invention is contained in an amount of 0.2% to 2% with respect to the liquid.

This is because the antiviral effect is insufficient when the content of the antiviral agent of the present invention is less than 0.1%.

Further, if the content of the antiviral agent of the present invention in the liquid is 0.2% or more, a sufficient antiviral effect can be expected.

Further, when the content of the antiviral agent of the present invention exceeds 2%, the problem of alkalinity becomes large as compared with the effect of the antiviral agent of the present invention.

The upper limit of the content of the antiviral agent of the present invention in the liquid is 25% or less in consideration of the slurry concentration.

The liquid may be water, or an alcohol such as methanol, ethanol, or isopropyl alcohol, or a mixed liquid of such an alcohol and water.

Further, the liquid to be added to the spray bottle may be a liquid containing chlorhexidine, benzalkonium chloride, benzethonium chloride, alkyl polyamino ethyl glycine, or other amphoteric surfactant.

Accordingly, the antiviral agent of the present invention is partially ionized in the spray bottle, and the rest is in a state of being precipitated in the spray bottle.

Before use, the user shakes the spray bottle. Accordingly, in the spray bottle, water and the antiviral agent of the present invention precipitated in the spray bottle are mixed to obtain a white suspension.

Subsequently, a white suspension was sprayed onto the area considered to be contaminated with viruses.

In contrast to the conventional practice of spraying alcohols and sodium hypochlorite solutions exclusively in places where viral contamination is expected, since alcohols are volatilized, and thus long-term maintenance of antiviral effect cannot be expected, when the white suspension of the present invention is sprayed in places where viral contamination is expected, the white suspension contains calcined dolomite and is partially hydrolyzed to obtain powder, which is nonvolatile, and long-term maintenance of antiviral effect is expected in places where viral contamination is expected.

Further, the white suspension is dried in the place where the white suspension is sprayed, and thus a thin white powder is formed, and the antiviral agent of the present invention can easily distinguish the place where the antiviral agent has been sprayed from the place where the antiviral agent has not been sprayed, and thus it is easy for the operator to spray the antiviral agent in the place where the operator is considered to be contaminated with the virus.

Furthermore, the place where the white suspension is sprayed can be easily restored to the original state by wiping with a rag.

Further, when the white suspension is sprayed on the face mask surface side using the spray bottle, a conventional face mask can be made into a face mask for preventing infection with Severe Acute Respiratory Syndrome (SARS) virus, influenza virus, or the like.

Further, although the spray bottle is used as an example of the container, the antiviral agent of the present invention and water are contained in the container, and after they are continuously mixed, clothes and other parts are impregnated with the mixture to provide an antiviral effect, and thus, a virus removal operation for clothes and other parts contaminated with viruses can be performed.

The spray bottle is not particularly limited as long as it is a conventionally known spray bottle, and may be a pump type spray bottle or a pressurized type spray bottle using a gas such as ethylene gas.

(example 8)

Comparison of the antiviral effects of the antiviral agent of the present invention and other inorganic materials is illustrated here.

First, a sample shown in fig. 2 was prepared.

Also, sample No.10 and sample No.11 in FIG. 2 are antiviral agents of the present invention.

Further, fig. 2 shows the composition (chemical formula), average particle diameter (μm), and specific surface area (m) of each sample²In terms of/g). Note that the manufacturer and the grade of the sample used are described in the comment of fig. 2.

Subsequently, 0.1ml of each suspension or solution of the samples shown in FIG. 2 was added to a 1.5ml microtube, and 0.9ml of a virus solution (an example of influenza A/コハクチョウ/Ishige root/499/83 (H5N3) (strain isolated from birds)) was added thereto to prepare a solution having a final concentration of 0.3% or 0.17%.

After the preparation, a predetermined time (10 minutes) has elapsed, 90. mu.l of each suspension or solution of each sample to which a virus solution was added prepared as described above was collected on average, added dropwise to a test tube to which 0.81ml of a diluent of PBS (phosphate buffered saline (PBS) having a pH of 7.2) was added, diluted to a concentration 10-fold, and mixed thoroughly. This operation was repeated 9 times to prepare 10^-1、10^-2、10^-3、10^-4、10^-5、10^-6、10^-7、10^-8、10^-9The diluent of (1) was used in an amount of 10^-2、10^-3、10^-4、10^-5、10^-6、10^-7、10^-8、10^-9The dilution of (3) was subjected to the experiment.

Each diluted mixed virus solution was inoculated into the urinary cavity of 3 SPF-developed eggs of 10 days of age, each inoculated with 0.2 ml.

After inoculating each diluted mixed virus solution to a developing egg, culturing for 3 days, recovering allantoic fluid, reacting with 0.5% suspension of chicken red blood cells, and judging whether the virus is increased or not according to the presence or absence of agglutination of the chicken red blood cells.

Next, the virus titer was calculated according to the method of Reed and Muench (ref: Reed, L, J,. Muench, H.: A simple method of simulating flame per center points. am. J. Hyg.27, 493-497 (1938)).

The above results are shown in fig. 3 and 4.

Further, experiments were carried out this time on the mixture (sample No.9) of calcium hydroxide (sample No.2), calcium oxide (sample No.1), slaked lime (sample No.7), calcium hydroxide and magnesium hydroxide mixed in a ratio of 1:1, the article of the present invention (sample No.10 and sample No.11) having the same number of moles as that of calcium.

As a result, the virus titers of the present invention product (sample No.10), calcium hydroxide (sample No.2) and the present invention product (sample No.11) were 10 in this order^5.00、10^5.50、10^5.50The samples of the invention were significantly lower in infection titer in this experiment compared to the other samples.

Further, the mixture of calcium hydroxide and magnesium hydroxide mixed at a ratio of 1:1 (sample No.9) had a virus titer of 10^6.25And, the viral titer of slaked lime (sample No.7) was 10^6.50. Furthermore, the virus titer of calcium oxide (sample No.1) was found to be<10^7.50。

(example 9)

The chemical composition of the dolomite used, the reaction upon heating the dolomite and the results of the analysis of the chemical composition of the antiviral agent of the present invention are explained here.

FIG. 5 shows the chemical composition (X-ray diffraction results) of the dolomite used.

Further, FIG. 6 shows the chemical composition (X-ray diffraction result) of a product obtained by preliminarily calcining (calcining) dolomite.

Also, fig. 7 shows the chemical composition (X-ray diffraction result) of the powder (antiviral agent of the present invention) obtained by calcining (calcining) dolomite and partially hydrating (digesting) the dolomite.

Here, when dolomite is heated, a reaction represented by the following formula occurs in a temperature range of 750 to 800 ℃ to start MgCO₃And (4) digesting.

CaMg(CO₃)₂→CaCO₃+MgO+CO₂↑

Then, in the temperature range of 900 to 1000 ℃, a reaction represented by the following formula is generated to cause CaCO₃And (4) digesting.

CaCO₃+MgO→CaO+MgO+CO₂↑

Thus, the powder (antiviral agent of the present invention) obtained by calcining (calcining) the dolomite of the present invention and partially hydrating (digesting) the dolomite is considered to have an antiviral effect due to CaO produced at the stage of calcining (calcining) the dolomite of the present invention (for this, refer to the results of the antiviral experiment of sample No.1 in FIGS. 3 and 4.)

Here, the chemical composition (X-ray diffraction result) of the powder (antiviral agent of the invention) obtained by calcining (calcining) dolomite and partially hydrating (digesting) it, is exclusively CaCO, see FIG. 7₃、Ca(OH)₂And Mg (OH)₂. This is considered to be the powder obtained by calcining (calcining) dolomite and partially hydrating (digesting) the dolomite, the hydrated (digested) portion being exclusively indicated as CaCO₃、Ca(OH)₂And Mg (OH)₂。

However, based on the results of the antiviral experiments shown in FIGS. 3 and 4, the products of the present invention (sample No.10 and sample No.11) were reacted with Mg (OH)₂(sample No.4), Ca (OH)₂And Mg (OH)₂The mixture (sample No.9) mixed at a ratio of 1:1 exhibited a higher antiviral effect than that of the mixture, and as shown in FIG. 2, the products of the present invention (sample No.10 and sample No.11) wereThe products of the present invention (sample No.10 and sample No.11) were different in the antiviral effect by CaO, because of the large specific surface area compared with CaO (sample No.1), and it is considered that except for CaO, Ca (OH)₂、Mg(OH)₂In addition to the antiviral effect, the antibacterial agent is produced by the large specific surface area and the intermediate (primary calcined dolomite) (containing MgO CaCO)₃Mixture of (2), containing MgO, Mg (OH)₂、Ca(OH)₂And CaCO₃Or a mixture of (A) and (B) containing Mg (OH)₂、Ca(OH)₂And CaCO₃Mixtures of (b), (c), etc.) can exert high antiviral effects.

(example 10)

There is illustrated a preferred example of an antiviral component of the present invention, here a face mask using an antiviral agent of the present invention.

In fig. 8, (a) and (b) are perspective views showing the appearance of a face mask using the antiviral agent of the present invention.

First, in fig. 8, (a) shows a mask 1 including a filter member 2, fixing members (in this example, band members made of an elastic material such as rubber) 3 and 3 provided on both side surfaces of the filter member 2 and fixed to both ears of a person in use, and a string member 4 provided to be accommodated in an upper portion of the filter member 2.

The string member 4 is a member for improving the airtightness in the range from the cheek to the nose of a human when used in a shape that fits the cheek to the nose of the human by plastic deformation together with the mask 1.

In addition, in this mask 1, as shown in fig. 8(a), 3 pleats 5, 5 are provided in the lateral direction on the filter member 2 so as to extend along the cheek of a person to the chin, thereby making it easier to provide the mask 1 with airtightness.

Further, the mask 11 shown in fig. 8(b) includes a filter member 12, a pair of fixing members (in this example, band members formed of an elastic body such as rubber) 13, 13 provided at both ends of the filter member 12 so as to bridge between the ends, and a wire member 14 provided to be housed in an upper portion of the filter member 12.

The string member 14 is a member for improving the airtightness in the range from the cheek to the nose of a human together with the mask 11 when it is used in a shape that fits the cheek to the nose of the human by plastic deformation, like the string member 4.

When a person wears the mask 11, one of a pair of fixing members (in this example, a band member made of an elastic material such as rubber) 13, 13 is placed at a position near the neck so as to wrap around the position near the neck, and the other is wrapped around the back of the head.

In the mask 11, the filter member 12 is formed in a three-dimensional shape of a bowl, a concave portion is formed in a central region thereof, and a portion 12a located in the concave portion of the filter member 12 is creased in a substantially square shape to form a top portion thereof.

Since the mask 11 has the above shape and structure, when a person wears the mask 11, the sealing between the face and the mask 11 is improved, and breathing is facilitated.

Next, the structure of the filter member 2 of the mask 1 shown in fig. 8(a) will be described.

Fig. 9 is a sectional view schematically showing the structure of the filter member 2 of the mask 1 shown in fig. 8 (a).

In fig. 9, (a) is a schematic view showing a state in which dust, pollen p, bacteria b, viruses w, and the like in air inhaled from the outside by a person are blocked when the mask is used, and (b) is a schematic view showing a state in which the bacteria b, viruses w, saliva, and the like are blocked when the person exhales to the outside when the mask is used.

The filter element 2 includes a first cover 31, a second cover 32, a third cover 33, and a fourth cover 34.

The first cover 31 is the outermost cover when the mask 1 is worn by a person, and is mainly used for blocking dust, pollen p, bacteria b, and the like in the air.

In the second cover 32, an article coated with or mixed with the antiviral agent of the present invention is used. In this example, a nonwoven fabric coated with or mixed with the antiviral agent of the present invention is used. Virus w is killed as it passes through the moiety.

The third cover 33 uses a filter having hydrophobicity. The third coating has a small mesh size and can trap particles of about 3 μm.

The fourth cover 34 is made of the same material as the first cover 31. Here, a material having low skin irritation is used.

The mask 1 is provided with a third covering body 33 and a fourth covering body 34 on the skin side, the second covering body 32 not being in direct contact with the skin.

In fig. 8, when a person wears the mask 1 shown in fig. (a), dust, pollen p, bacteria b, and the like in the air are blocked by the first covering body 31, viruses are killed by the second covering body 32, the third covering body 33 is used to capture particles and nuclei of droplets having diameters in the range of 1 to 51 μm, and the fourth covering body 34 is used to protect the skin.

Moreover, when a virus infected person wears the mask 1, the situation that surrounding people are infected by the virus droplet nuclei can be remarkably reduced.

Although the center of the mask 11 is described above, the structure of the filter member 12 of the mask 11 shown in fig. 8(b) is the same as the structure of the filter member 2 of the mask 1 shown in fig. 9, and the effects thereof are also the same, and therefore the description thereof is omitted here.

The mask 11 is qualified by standard inspection of NIOSH (national institute of labor safety and health), a national institute of health and safety), which is a subordinate agency of the disease control center (CDC), and is provided with a filter capable of blocking 95% or more of fine particles having a size of 0.3 μm or more, and is named as "N95 mask".

Industrial applicability

Can prevent severe acute respiratory system infectious diseases (SARS) virus and influenza virus.

Claims (6)

1. An antiviral agent comprising a powder obtained by calcining dolomite at a temperature of 700 ℃ to 1300 ℃ for 14 hours to 15 hours, partially hydrating the dolomite until the moisture content of the partially hydrated product is 3 w/w% to 7 w/w%, and pulverizing or screening the partially hydrated product until the secondary particles have an average particle size of 0.1 μm to 60 μm.

2. A fiber which retains the antiviral agent according to claim 1.

3. An antiviral agent comprising the fiber according to claim 2.

4. An antiviral agent comprising the antiviral agent according to claim 1 in a liquid.

5. An antiviral agent pack comprising the antiviral agent according to claim 4 in a container.

6. The antiviral member as claimed in claim 5, wherein said container is a spray bottle.